Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. executive chairman Matthew Rabinowitz reported insider transactions involving the company’s common stock. On July 6, 2026, his spouse completed an open‑market sale of 1,000 shares at $280 per share under a pre‑arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following this sale, indirect holdings by his spouse totaled 4,000 shares, while Rabinowitz’s direct ownership stood at 2,277,843 shares, indicating the sale was small relative to his overall position.
Natera, Inc. insider Daniel Rabinowitz, the Secretary and Chief Legal Officer, sold 16,800 shares of Common Stock in a series of open‑market transactions. The sales occurred on July 1, 2026 and were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 5, 2025.
The reported sales were broken into multiple trades at weighted‑average prices, with underlying individual trade prices ranging from about $266.33 to $278.78 per share, according to the footnotes. The filing does not change any company fundamentals; it simply discloses these planned insider stock sales.
Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported selling 3,000 shares of Natera common stock in open-market transactions on July 1, 2026. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024, indicating the trades were scheduled in advance. Reported weighted average prices were about $274.06, $272.99, and $267.19 per share, with actual trade prices ranging between $267.05 and $273.00. Moshkevich continues to hold a direct equity stake in Natera after these sales.
Matthew Rabinowitz reported multiple sales of Common stock as disclosed on Form 144. The filing lists two 50,000-share sales on 06/15/2026 and 06/12/2026, and several smaller dispositions between 04/28/2026 and 05/06/2026. Each transaction shows the share count and gross proceeds.
Natera, Inc. reported that Monica Bertagnolli has resigned from its Board of Directors and all board committees, effective July 1, 2026. She is leaving due to her new position with the National Academy of Medicine. The company states her resignation is not related to any disagreement over operations, policies, or practices.
NTRA files a Form 144 reporting proposed insider sales of Common Stock. The notice lists a 10b5-1 sale of 33,600 shares for $8,455,352.64 on 06/24/2026, plus earlier 10b5-1 transactions of 1,861 shares for $379,811.07 on 04/27/2026 and 330 shares for $68,032.80 on 05/01/2026. The form also references 16,800 shares from previously exercised options dated 01/14/2022.
Solomon Moshkevich filed a Form 144 reporting proposed and recent sales of Common Stock. The notice lists 3000 performance shares identified with an issuer sale date of 01/14/2026. The filing also records multiple sales by Moshkevich between 04/28/2026 and 06/01/2026, including transactions of 3,000, 1,652, 408, 3,000, 1,249, and 1,015 shares with corresponding proceeds shown in the excerpt. The filing lists an aggregate contextual figure of 143,215,382 shares with an associated date of 07/01/2026.
Rubin Eric H reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. director Eric H. Rubin received a grant of 75 Restricted Stock Units (RSUs) of Common Stock as part of his board compensation. The award was issued in lieu of quarterly retainer fees of $16,875 and was fully vested at the time of issuance. Each RSU represents a right to receive one share of Natera common stock, and following this grant Rubin holds 2,204 shares directly.
Natera, Inc. director Herm Rosenman reported two equity compensation awards in the form of restricted stock units (RSUs). The filing shows awards covering 106 shares and 1,571 shares of Common Stock, both recorded as acquisitions with no cash paid per share.
One RSU grant will vest in full on June 11, 2027 and will become fully vested earlier if Natera undergoes a change in control. The other RSU award was issued in lieu of quarterly board retainer fees of $23,750 and was fully vested upon issuance, effectively substituting stock-based compensation for cash fees.
Marcus Gail Boxer reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. director Marcus Gail Boxer reported two stock-based compensation awards in the form of restricted stock units (RSUs). He received 98 RSUs that vest in full on June 11, 2027, and these RSUs will become fully vested if Natera undergoes a change in control before that date.
He also received 1,571 RSUs in lieu of $21,875 in quarterly cash retainer fees for serving on the board. These RSUs were fully vested when issued. Each RSU represents a right to receive one share of Natera common stock, so these are non-cash equity grants rather than open-market share purchases.